Teva Reports Full Year And Fourth Quarter 2016 Financial Results

Published: Feb 13, 2017

JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) today reported results for the year and the quarter ended December 31, 2016.

“While we continue to manage through a turbulent and constantly evolving industry, we are committed to execute against our strategy with more diversified revenue sources and profit streams, all backed by strong product development engines in both generics and specialty.”

FY 2016

Q4 2016

Revenues $21.9 billion $6.5 billion
Cash flow from operations $5.2 billion $1.4 billion
GAAP EPS $0.07 ($1.10)
Non-GAAP EPS $5.14 $1.38
Teva reaffirms its 2017 full year non-GAAP guidance;
including revenues of $23.8 - 24.5 billion, and
non-GAAP EPS of $4.90 - 5.30

“2016 was a transitional year for Teva – one that included significant achievements, as well as challenges,” stated Dr. Yitzhak Peterburg, Interim President and CEO of Teva. “While we continue to manage through a turbulent and constantly evolving industry, we are committed to execute against our strategy with more diversified revenue sources and profit streams, all backed by strong product development engines in both generics and specialty.”

Back to news